Scholar Rock Holding Corp (NASDAQ: SRRK) has recently seen a surge in bearish put options activity, raising questions about the company’s outlook. SRRK is a late-stage biopharmaceutical company focusing on therapies for muscle disorders, most notably apitegromab for spinal muscular atrophy (SMA) (^[1]). Following a breakthrough Phase 3 trial in late 2024 – where apitegromab significantly improved motor function in SMA patients – SRRK’s stock price exploded over 300% (^[1]). The optimism propelled its market capitalization above $3 billion, with shares recently trading around $34 (^[2]) (^[2]). However, an unusual build-up in open put options (with a put/call open interest ratio of 1.86 (^[3])) and short interest near 21% of float (^[4]) suggests that some traders are betting on challenges ahead. This report dives into SRRK’s fundamentals – from its zero-dividend policy to its debt structure, valuation, and key risks – to understand why bearish sentiment may be rising and what it means for investors.

Dividend Policy & Cash Yield

What’s inside the FREE 2025 Wealth Protection Guide?

• Why physical gold outlasts economic storms
• How to move 401(k)/IRA/TSP into a Gold IRA tax-free
• Privatize your retirement from market & government risk

Download the Free Guide →

Scholar Rock pays no dividend, in line with typical development-stage biotechs. The company has never declared cash dividends and does not intend to do so in the foreseeable future, opting to reinvest any future earnings into R&D (^[5]). As a result, SRRK’s dividend yield stands at 0.00% (^[6]). Since the company currently generates no positive earnings or free cash flow from operations, traditional payout metrics like AFFO or FFO are not applicable. In fact, SRRK consistently incurs net losses and negative operating cash flow, funding its activities through capital raises rather than internal cash generation (^[5]). For example, in the first half of 2025 the company used $155.6 million in cash for operations (up from $99 million in H1 2024) (^[7]), underscoring its dependence on external funding. This cash-usage profile means investors’ returns hinge entirely on stock price appreciation, not dividends (^[5]).

Leverage and Debt Maturities

Despite its pre-revenue status, Scholar Rock has taken on long-term debt to extend its cash runway. In February 2025, SRRK amended and upsized its loan facility with Oxford Finance, increasing borrowing capacity to $200 million across four tranches (^[5]). To date, $50 million has been drawn (from earlier $25M + $25M tranches in 2020–2021), and additional $50M tranches remain available through 2025, 2026, and 2027 contingent on achieving certain milestones (^[5]) (^[5]). Crucially, the debt’s terms are very favorable in the near term: Scholar Rock secured an interest-only period through March 2029, with no principal repayments due until April 2029 (^[5]). The loan’s maturity was extended to February 1, 2030 (potentially to 2031 if further milestones are met) (^[5]). Interest accrues at 1-month SOFR + 5.5% (with a 3% SOFR floor), meaning an effective rate around 9–10% given current benchmarks (^[5]). This venture debt also carries a modest 2% final fee and certain covenants (e.g. requirements to maintain sufficient cash relative to debt) (^[5]) (^[5]). No other significant long-term liabilities have been disclosed beyond standard leases and the warrant liabilities from past financings. Overall, SRRK’s debt maturities are pushed far into the future (2030), aligning with the timeline by which its lead drug could be commercialized and generating revenue.

Liquidity & Coverage

Scholar Rock’s liquidity position remains strong in the near term, bolstered by recent financing. After an upsized $300 million equity offering in October 2024 at $28.25 per share (^[8]) (^[8]) (plus a $45 million overallotment exercised by underwriters (^[9])), SRRK ended 2024 with approximately $437 million in cash, equivalents, and investments (^[7]) (^[7]). As of June 30, 2025, cash and marketable securities still totaled $295 million (^[7]). Management believes this war chest, plus the undrawn debt tranches, is sufficient to fund operations into 2027 (^[7]). Notably, SRRK’s interest obligations are easily covered by its cash on hand and investment income. The $50M term loan carries roughly ~$5M in annual interest expense, which is partly offset by interest income earned on the company’s large T-bill portfolio (^[7]). Indeed, in recent periods Scholar Rock’s interest income on its cash (thanks to higher rates) has substantially offset its interest expense (^[7]). With no debt principal due for over 4 years, the immediate solvency risk is low. However, the coverage of long-term needs is not assured: management openly acknowledges that additional capital will be required to fully fund commercialization and pipeline development beyond the current runway (^[7]). In other words, absent product revenue, SRRK will likely need to raise more funds or draw more debt by 2027, which could dilute shareholders or add interest costs.

Valuation and Comparable Metrics

Traditional valuation metrics like P/E or P/FFO are not meaningful for SRRK, given its negative earnings and minimal revenue. Investors instead value the company based on its pipeline prospects and potential future cash flows. Following the successful Phase 3 trial for apitegromab, analysts projected peak annual sales of around $1.2–2 billion for the drug by the early 2030s (^[1]) (^[10]). This substantial revenue opportunity underpins Scholar Rock’s multi-billion dollar market cap. At ~$34 per share (market cap ≈ $3.1 B), the stock is effectively trading at a high multiple of its book value – Price-to-Book is about 13× (with $233 M equity as of mid-2025) – and an astronomical multiple of current sales (trailing 12-month revenue was only ~$33 M from collaborations (^[6])). Such valuation is typical of late-stage biotech: the market is pricing in expectations of future success rather than present fundamentals. For context, analysts expect next-generation weight-loss and muscle-preserving drugs (the category SRRK aims to enter) could achieve $1–5 B in annual sales by decade’s end (^[11]). If apitegromab captures even a portion of that market (through SMA and potential obesity indications), SRRK’s current ~$3B enterprise value could be justified or even modest. On the other hand, the valuation leaves little margin for error. Any setbacks (delays, failure to commercialize, or competition) could compress the lofty EV/future-sales multiples. In summary, SRRK’s valuation reflects big hopes for apitegromab’s commercial impact, alongside recognition that the company’s entire ~$3B value rests on unproven assets.

Key Risks and Challenges

– Regulatory and Manufacturing Risk: Scholar Rock recently faced a regulatory setback when the FDA declined to approve apitegromab in Sep 2025 due to manufacturing issues at a third-party facility (^[10]). The FDA’s rejection was not about the drug’s efficacy but rather quality problems at Catalent’s fill-finish plant (now owned by Novo Nordisk) (^[10]). This has delayed apitegromab’s launch and caused a 12% drop in SRRK’s share price on the news (^[10]). While the company plans to refile its application within ~3 months once the manufacturing issues are resolved (^[10]), any further delays or compliance problems could push back revenues and increase cash burn. Regulatory timing is critical: each month of delay in approval is a month without product sales to offset expenses.

– Single-Product Concentration: Apitegromab is the cornerstone of Scholar Rock’s strategy and valuation (^[10]). The company currently has no other late-stage products; its pipeline (e.g. SRK-181 in early trials for immuno-oncology) is years behind. This concentration amplifies risk – if apitegromab encounters any clinical, safety, or commercial hurdles, SRRK has no alternative revenue source to fall back on (^[5]). Even assuming approval, market adoption is not guaranteed. Doctors might be hesitant to prescribe apitegromab on top of existing SMA therapies; for example, some physicians **“may deem it sufficient to treat SMA with an SMN-targeted drug (like Biogen’s nusinersen or Roche’s risdiplam) and therefore not utilize apitegromab alongside those” (^[7]). If apitegromab is used only in a subset of patients or faces pushback from insurers on cost, its sales could underwhelm relative to current high expectations.

– Commercialization and Execution: Transitioning from R&D to commercialization poses a big challenge for Scholar Rock. The company will need to build or outsource a sales and marketing infrastructure for a rare disease like SMA – a domain dominated by much larger players. Successfully launching an injectable biologic to a small, dispersed patient population requires significant expertise and investment. Any missteps in manufacturing scale-up, physician education, or patient outreach** could slow apitegromab’s uptake. Moreover, SRRK must navigate pricing and reimbursement for a novel SMA add-on therapy. Payers will demand evidence of functional benefit (e.g. improved strength or quality of life) to justify costs. In weight-loss usage, FDA approval standards will be high, requiring proof of health benefits beyond just muscle mass (such as better mobility or reduced falls) (^[11]). Meeting these bars will not be trivial, and failure to do so could limit the drug’s market.

– Competition and Innovation: Scholar Rock faces emerging competition in muscle-preserving therapies from both small biotechs and industry giants. For SMA, current standard-of-care (Spinraza, Evrysdi, and Novartis’s gene therapy Zolgensma) have set a high efficacy bar in preventing disease progression. Apitegromab is differentiated as a muscle-targeted add-on, but competitors could develop their own muscle enhancers. In the broader muscle preservation market (especially for obese patients on GLP-1 weight-loss drugs), multiple programs are in development. For instance, Veru’s enobosarm (a SARM) and Eli Lilly’s bimagrumab (an antibody) have shown promising results in reducing muscle loss when combined with obesity drugs (^[11]). Regeneron recently reported that its antibody trevogrumab + semaglutide preserved ~80% of lean muscle in a mid-stage trial (^[12]). These competitors – some potentially reaching the market by 2027 – could capture the opportunity that Scholar Rock is targeting. If apitegromab’s profile is not clearly superior or if it lags in entering the obesity-related segment, SRRK may find itself an also-ran in a field it helped pioneer. Essentially, big pharma entrants and other biotechs pose a material threat to the long-term growth story.

– Financial and Dilution Risk: As noted, Scholar Rock will burn cash for at least several more years developing apitegromab’s additional indications and supporting its launch (^[5]). The company estimates its existing cash will fund operations through 2026 into 2027 (^[7]). Beyond that, unless apitegromab generates substantial revenue by then, SRRK will require additional financing (^[7]). This could come via issuing more equity (diluting existing shareholders) or taking on more debt. Indeed, SRRK’s history shows frequent capital raises: e.g. a large follow-on equity offering in late 2024 and past stock+warrant financings in 2020 and 2022 (^[8]) (^[7]). Likewise, 17.4 million “pre-funded” warrants are outstanding (from prior offerings) which can convert to common shares for a nominal price (^[7]) – these represent future dilution. If the share price weakens, raising new equity becomes harder and more dilutive, creating a financing Catch-22. Additionally, while the Oxford loan mostly defers principal, it restricts certain actions (like paying dividends or incurring new liens) (^[5]) (^[5]) and could be a burden if the company ever breached covenants. Overall, SRRK’s finances are stable for now, but longer-term funding needs present a risk that could pressure the stock.

Red Flags and Notable Signals

Beyond the fundamental risks, several red flags have emerged that may explain the surge in bearish options positioning:

– Unusual Bearish Sentiment Indicators: Options markets and short sellers are flashing warning signs on SRRK. The open interest in put options has spiked to levels well above call OI – the put/call ratio of 1.86 is unusually high (^[3]), indicating nearly twice as many bearish bets as bullish. In fact, one near-term expiry (Oct 2025) shows over 17,000 puts outstanding, a striking number that suggests a large trader (or group) may be hedging or speculating on a decline (^[3]). Likewise, short interest stands at ~16.8 million shares, which is ~21% of SRRK’s public float (^[4]) – an elevated level for any stock. It would take nearly 6 days of average trading volume for shorts to cover their positions (^[4]). This heavy short exposure can be a self-reinforcing red flag: it reflects skepticism from sophisticated investors about SRRK’s valuation or upcoming catalysts, and it can put technical selling pressure on the stock. Such bearish sentiment is notable given SRRK’s recent clinical success, suggesting some insiders or informed parties see uncertainties that others might be overlooking.

– Insider Selling: Another red flag is insider stock sales by key executives. Notably, Edward “Ted” Myles, SRRK’s COO and CFO, unloaded a large portion of shares through multiple transactions in late 2024 and early 2025. According to SEC filings, Mr. Myles sold roughly 172,240 shares (netting about $5.1 million) in March 2025 (^[13]), following sales of a similar magnitude in August 2024 (^[14]). While he also exercised some stock options to acquire shares, the net effect was a significant reduction in his holdings (^[13]). Frequent or substantial insider selling – especially by the financial chief – can signal that management perceives the stock as fully valued or that they’re locking in gains. It does not necessarily mean doom (executives have personal reasons to diversify), but the timing is eyebrow-raising: the CFO’s sales came ahead of critical milestones, including the FDA filing and decision. Investors often view such sales as a potential lack of confidence in the stock’s near-term upside, adding to the bearish narrative.

– High Expectations Priced In: The flip side of SRRK’s lofty valuation is that any slip-up can punish the stock severely. We saw a glimpse of this when the FDA’s delay news, which was arguably a temporary issue, knocked the stock down more than 10% in one day (^[10]). The market has little tolerance for surprises at these levels. The presence of pre-funded warrants (over 17 million) and large holders from the recent offering also means there could be selling pressure as lock-ups expire or as those warrants convert, which could cap rallies. Additionally, SRRK will soon no longer qualify as a “smaller reporting company” due to its high market cap (^[7]), meaning heightened disclosure and compliance requirements – a minor point, but one that adds overhead and could modestly increase administrative costs. In total, these factors paint a picture that SRRK’s stock is under a microscope, and bearish traders are actively positioning for downside or protection.

Open Questions and Outlook

Despite the red flags, Scholar Rock’s story is far from over – several open questions will determine where SRRK goes from here:

– When (and under what conditions) will apitegromab get approved? The company expects to refile the BLA within a few months (^[10]) after resolving the manufacturing deficiencies. Will the FDA require any additional clinical data or inspections, or will approval be swift once Catalent’s issues are fixed? A quick approval in 2026 could vindicate bulls, whereas any prolonged delay (or worse, a need for a new trial) would reinforce the bears’ case.

– How strong will apitegromab’s launch be in SMA? If approved, can SRRK convince neurologists and patients to add an extra infusion to their existing SMA regimens? Uptake will depend on real-world benefits. An open question is whether payers will reimburse apitegromab widely – insurers may wait for evidence of improved functional outcomes or long-term data on muscle development. Early sales trajectories in the first year post-launch will be a critical gauge of commercial viability.

– Will Scholar Rock tap a commercial partner or acquirer? Building a rare-disease sales force from scratch is expensive. One strategic path could be partnering with a larger biotech/pharma for marketing apitegromab (particularly ex-US). Alternatively, SRRK itself could become an acquisition target given its niche leadership – companies like Biogen, Roche, or Novartis (all active in SMA) might find apitegromab complementary to their portfolios. No such deal has been announced yet, but any signs of partnership discussions or M&A interest could dramatically shift sentiment (and likely force shorts to cover).

– Can SRRK expand into the obesity muscle-preservation market? This is a tantalizing longer-term question. Scholar Rock has indicated plans to explore apitegromab in patients on GLP-1 weight-loss drugs (to counteract muscle loss) (^[1]). Success here could open up a multi-billion dollar opportunity beyond SMA. However, the path to approval in obesity is challenging – requiring new trials, likely higher doses or different regimens, and demonstrating tangible health benefits (strength, mobility, etc., not just muscle mass) (^[11]). Moreover, competition is fierce (as discussed, Regeneron, Lilly, Veru and others are already in the clinic). An open question is whether apitegromab’s mechanism (myostatin inhibition) will prove safe and effective in metabolic disease populations. Any clinical data readouts in this arena (perhaps initial results in 2025 or 2026) will be pivotal for SRRK’s “second act.”

– How will future financing needs be met? While SRRK’s cash can carry it into 2027, large expenses loom – e.g. scaling up manufacturing, potential Phase 4 studies, and possibly expanding headcount for commercialization. If apitegromab launches well, it could start to offset some burn. If not, will the company draw another $50M debt tranche, issue new equity via an ATM facility, or seek another big raise? The dilution overhang is on investors’ minds. In the best case, positive progress could lift the stock high enough to raise capital opportunistically on strong terms (or avoid it via partnership revenues). In the worst case, a depressed share price and ongoing cash burn could force a highly dilutive financing – which is what the bearish option bets seem to anticipate. Monitoring SRRK’s quarterly cash burn rate and management’s commentary on runway will be key to answering this question.

In conclusion, Scholar Rock (SRRK) sits at a crossroads. The company has achieved a remarkable scientific milestone in demonstrating apitegromab’s benefits for SMA, earning it a rich valuation and high expectations (^[10]). Yet, the road from clinic to market is rarely smooth. The surge in put options activity and heavy short interest reflect legitimate concerns – from regulatory timing and commercial execution to competition and financing. Investors should closely watch the forthcoming FDA interactions and any guidance on launch timing, as these will likely dictate the next big move in the stock. A swift approval and strong early sales could trigger a short squeeze, given the nearly 6 days-to-cover short position (^[4]). Conversely, any stumble could see bearish bets pay off, pressuring shares further. As always with biotechs, the risk-reward is extreme. SRRK’s story exemplifies this: it could revolutionize care in SMA (and beyond) – or it could struggle under the weight of its own ambitions. The coming quarters, and the resolution of today’s bearish signals, will tell which scenario unfolds.

Sources:

1. Reuters – FDA declines to approve apitegromab (manufacturing issues) (^[10]) (^[10]); Phase 3 trial success and 300% stock jump (^[1]) (^[1]). 2. Company 10-Q (Q2 2025) – No dividend policy and retained earnings strategy (^[5]); debt facility terms (tranches, interest-only to 2029, maturity 2030) (^[5]) (^[5]); liquidity runway into 2027 and need for additional capital (^[7]); net operating cash outflow in H1 2025 (^[7]); risk that SMA doctors may not adopt apitegromab (^[7]). 3. Company Press Releases – Oct 2024 $300M equity offering details (^[8]) (^[8]) and underwriters’ option exercise adding $45M (^[9]). 4. Fintel.io – Options and short interest data (put/call OI ratio 1.86, heavy put OI, ~20.9% of float short, ~5.7 days to cover) (^[3]) (^[4]). 5. Investing.com – Insider trading report on CFO Ted Myles selling ~$5.07M in shares (Mar 2025) and exercising options (^[13]). 6. Dividend.com/Macrotrends – Market cap ~$3.1B and 0% dividend yield (^[2]) (^[2]) (^[6]); sector comparisons and revenue estimate (^[6]). 7. Reuters & Reuters (Feb 2025) – Outlook for muscle-preserving weight loss drugs (Veru’s enobosarm, Lilly’s bimagrumab, etc., $1–5B potential market) (^[11]); Regeneron’s combo trial preserving muscle mass (^[12]).

Sources

1. https://reuters.com/business/healthcare-pharmaceuticals/scholar-rocks-genetic-disease-drug-meets-main-goal-late-stage-trial-2024-10-07/
2. https://dividend.com/stocks/health-care/biotech-pharma/biotech/srrk-scholar-rock-holding-corp/
3. https://fintel.io/sopt/us/srrk
4. https://fintel.io/ss/us/srrk
5. https://sec.gov/Archives/edgar/data/0001727196/000155837025010400/srrk-20250630x10q.htm
6. https://macrotrends.net/stocks/charts/SRRK/scholar-rock-holding/dividend-yield-history
7. https://br.advfn.com/noticias/EDGAR2/2025/artigo/96574131
8. https://scholarrock.gcs-web.com/news-releases/news-release-details/scholar-rock-announces-pricing-upsized-300-million-public
9. https://scholarrock.gcs-web.com/news-releases/news-release-details/scholar-rock-announces-closing-full-exercise-option-purchase
10. https://reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-approve-scholar-rocks-muscle-weakness-drug-2025-09-23/
11. https://reuters.com/business/healthcare-pharmaceuticals/next-generation-weight-loss-drugs-aim-save-muscle-2025-02-19/
12. https://reuters.com/business/healthcare-pharmaceuticals/regenerons-weight-loss-drug-helps-preserve-muscle-mass-study-2025-06-02/
13. https://in.investing.com/news/insider-trading-news/scholar-rocks-coo-and-cfo-sells-shares-worth-507-million-93CH-4719492
14. https://biospace.com/scholar-rock-appoints-edward-ted-myles-as-chief-financial-officer-and-head-of-business-operations

For informational purposes only; not investment advice.